Business Wire

Boomi Agentstudio Achieves Rapid Adoption, Solidifying Boomi Enterprise Platform as Choice for Agentic AI at Scale

8.10.2025 10:00:00 CEST | Business Wire | Press Release

Share

Boomi™, the leader in AI-driven automation, today announced that Boomi Agentstudio has achieved rapid adoption by both Boomi customers and partners. Customers like Lexitas, SPIE, and Avalara are already exploring the possibilities of Agentstudio, underscoring the Boomi Enterprise Platform's position as the platform of choice for agentic AI at enterprise scale. Building on this momentum, organizations around the globe have now deployed more than 50,000 AI agents in production, while Boomi and its partners have published over 300 agentic workflow templates on the Boomi Marketplace, helping organizations accelerate agentic transformation across industries.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251008374964/en/

Boomi Agentstudio Achieves Rapid Adoption, Solidifying Boomi Enterprise Platform as Choice for Agentic AI at Scale

Customers Scale AI Agents to Production

Since the general availability of Boomi Agentstudio in May 2025, enterprise adoption has surged, moving from experimentation to production at scale. In just a few months, customers have driven a 10X increase in the number of agents created, governed, and deployed — clear evidence of how quickly organizations are operationalizing AI with Boomi.

“Boomi Agentstudio is giving us the opportunity to reimagine what automation could look like in our business,” said John Baker, CIO, Lexitas. “The promise of orchestrating agents that act, adapt, and collaborate with teams cross functionally, has us excited about the potential to move far beyond simple task automation.”

Partners Drive Agent Innovation at Scale

Boomi’s partner ecosystem is also fueling momentum by leaning into Boomi Agentstudio to build and publish agents for customers to adopt directly. Today, Boomi and partners have delivered over 300 agentic workflow templates to the Boomi Marketplace, with new solutions added regularly. Built by leading systems integrators such as Tech Mahindra, Onepoint, Sage IT, and Jade Global, these agents enable customers to quickly access validated, ready-to-use solutions that address real-world business challenges while reducing the time and cost required to implement AI.

Atul Soneja, Chief Operating Officer, Tech Mahindra(NSE: TECHM), a leading global provider of technology consulting and digital solutions to enterprises across industries, said, “As enterprises race from AI experiments to production, the real inflection point lies in agentic automation that is governed, trustworthy, and measurable. By building and publishing AI agents on the Boomi Marketplace,Tech Mahindra can deliver proven, repeatable solutions to customers worldwide. The speed at which we can bring new offerings to market with Boomi is unmatched, and customers benefit immediately from ready-to-deploy agents.”

Trust and Control Define the Future of AI Agents

To balance rapid innovation with control, Boomi Agentstudio embeds governance directly into its design. From monitoring and anomaly detection to full agent lifecycle management, enterprises gain the safeguards required to unlock the benefits of agentic AI without compromising on trust or compliance.

Industry experts emphasize the importance of governance as enterprises scale AI agents into production. “As organizations move from experimenting with AI agents to running them in mission-critical environments, governance becomes non-negotiable,” said Nick Patience, Vice President and Practice Lead, AI Platforms at Futurum. “Without visibility and control, agents can create risk rather than value. Vendors that provide governance alongside cross-provider support are shaping the future of enterprise agentic transformation.”

“Customers are scaling AI agents into production, and partners are bringing new solutions to market at record speed, both powered by Boomi Agentstudio,” said Steve Lucas, Chairman and Chief Executive Officer at Boomi. “This dual momentum reflects the unique strength of the Boomi Enterprise Platform: empowering innovation while ensuring governance, trust, and enterprise-grade scale. Together with our customers and partners, we’re building the future of agentic transformation.”

The Next Step in Agentic Transformation

Boomi Agentstudio has rapidly evolved with new enterprise-grade capabilities designed to accelerate innovation, strengthen governance, and simplify AI adoption at scale.

  • Cross-provider agent governance - Enterprises can register and govern agents from Amazon, Salesforce, Microsoft, and custom accounts through open APIs all within Boomi Agent Control Tower. This provides a single source of truth for managing AI agents across the organization — delivering unmatched visibility and consistency.
  • Agent anomaly detection - Boomi continuously monitors agent behavior to detect irregularities in real time. This helps organizations resolve issues faster, better protect systems from potential breaches, and help ensure agents are always performing as expected.
  • Model Context Protocol (MCP) support - Boomi provides end-to-end MCP support by curating and exposing APIs, integrations, and services as reusable MCP-compliant tools that agents can seamlessly discover and consume. This empowers enterprises to securely extend their ecosystem and accelerate agentic outcomes, without the need to rebuild.
  • Predictable outcomes - With structured input/output (I/O), AI agents can communicate with business systems using predictable, machine-readable formats. This ensures smooth orchestration of multiple agents, reduces errors, and makes it easier to scale complex, production-ready workflows.
  • 300+ agentic workflow templates - Together with partners, Boomi provides a thriving ecosystem of more than 300 agentic workflows that address common use cases across departments and industries. These templates allow teams to get up and running quickly, skip generic starting points, and focus on tailoring agents to their specific business needs.
  • Centralized telemetry logs - All agent activity is captured in 30 days of telemetry logs. This gives enterprises complete visibility into both user and system actions, ensuring accountability, compliance, and operational control.

Building on the momentum of Agentstudio, the addition of Agent Step further extends Boomi’s leadership as the platform for agentic transformation. Agent Step embeds AI agents directly into integration processes within the familiar Boomi Process Canvas, putting intelligence right where developers work, right when they need it. By moving beyond static logic to real-time, context-aware decision-making, enterprises can unlock new levels of hyperproductivity and resilience in their automation workflows. In today’s AI-driven business landscape, this ability to seamlessly connect intelligence within integration processes is no longer optional — it is essential.

Additional Resources

About Boomi

Boomi, the leader in AI-driven automation, enables organizations worldwide to connect everything, automate processes, and accelerate outcomes. The Boomi Enterprise Platform — including Boomi Agentstudio — unifies integration and automation along with data, API, and AI agent management, in a single, comprehensive solution. Trusted by over 25,000 customers and supported by a network of 800+ partners, Boomi is driving agentic transformation — helping enterprises of all sizes achieve agility, efficiency, and innovation at scale. Discover more at boomi.com.

© 2025 Boomi, LP. Boomi, the ‘Boomi’ logo, the ‘B’ logo, and Boomiverse are registered trademarks of Boomi, LP or its subsidiaries or affiliates in the US and other countries. All rights reserved. Other names or marks may be the trademarks of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251008374964/en/

Contacts

Media:
Kristen Walker
Boomi Global Corporate Communications
kristen.walker@boomi.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye